Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,015.21 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Q4 2025 Earnings Call Transcript ↗

February 04, 2026

Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below.

Via Benzinga

Topics Earnings

Eli Lilly (LLY) Stock Trades Up, Here Is Why

February 04, 2026

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 10% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an...

Via StockStory

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

February 04, 2026

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.

Via The Motley Fool

Eli Lilly (LLY) Q4 2025 Earnings Call Transcript ↗

February 04, 2026

Eli Lilly (LLY) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Eli Lilly & Co. (NYSE:LLY) Soars on Blockbuster Q4 Earnings and Upbeat 2026 Guidance ↗

February 04, 2026

Via Chartmill

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

Via Stocktwits

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...

Via Stocktwits

Topics Intellectual Property

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

February 04, 2026

Via Chartmill

Q4 Earnings Summary: Eli Lilly And AbbVie Beat, Uber Mixed ↗

February 04, 2026

Quarterly earnings reveal a mix of positive surprises and challenges, with Eli Lilly and AbbVie beating expectations and Uber facing hurdles.

Via Talk Markets

Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double ↗

February 04, 2026

The drugmaker smashed Q4 expectations and guided up on its obesity treatments.

Via Investor's Business Daily

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Via Stocktwits

Eli Lilly (NYSE:LLY) Reports Strong Q4 CY2025, Stock Soars

February 04, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year...

Via StockStory

Does Stanley Druckenmiller Know Something Wall Street Doesn't? He Dumped All of His Shares in a Company Dominating a Market That May Soon Be Worth $100 Billion and Opened Positions in 3 AI Giants. ↗

February 04, 2026

Druckenmiller has renewed his AI bet.

Via The Motley Fool

Topics Artificial Intelligence

Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? ↗

February 03, 2026

Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.

Via Stocktwits

Topics Intellectual Property

Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics ↗

February 03, 2026

While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting-edge healthcare segment.

Via The Motley Fool

Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗

February 03, 2026

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.

Via The Motley Fool

Topics Initial Public Offering Intellectual Property Stocks

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

Via The Motley Fool

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

February 03, 2026

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

Via Barchart.com

Veteran Biopharma Engineer Ge Yang Attracts Investor Interest with Vision to Redefine Global Pharma Manufacturing

February 03, 2026

Via AB Newswire

If You Invested $100 In Eli Lilly and Co Stock 5 Years Ago, You Would Have This Much Today ↗

February 03, 2026

Via Benzinga

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

February 03, 2026

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Via Barchart.com

Topics ETFs

Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits ↗

February 03, 2026

Eli Lilly (LLY) Q4 Preview: Analysts predict a $17.9B revenue beat, but rising R&D costs could challenge the $6.96 EPS target.

Via Benzinga

Eli Lilly (LLY) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 02, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Wednesday before market hours. Here’s what to expect.

Via StockStory

Google Stock Hits Record High, Leads Select Group Of 14 Stocks Onto Best Stock lists ↗

February 02, 2026

Search and AI data center king Google closed at 343.69 Monday. It was up 1.7% for the day and popped to a record close.

Via Investor's Business Daily

Topics Artificial Intelligence

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Via TokenRing AI

Topics Artificial Intelligence

Is Novo Nordisk Stock a Bargain Right Now? ↗

February 02, 2026

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

Via The Motley Fool

VenHub Appoints Former Amazon Executive, Ian Rasmussen, to Spearhead Nationwide Smart Store Expansion with Focus on Strategic Partnerships and Enterprise Integrations

February 02, 2026

VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as

Via PressReach

3 Headwinds Facing Pfizer in 2026 ↗

February 02, 2026

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Via The Motley Fool

Topics Intellectual Property

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.